FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896745557> ?p ?o ?g. }

• W2896745557 endingPage "69" @default.
• W2896745557 startingPage "62" @default.
• W2896745557 abstract "•A patient with multiple sclerosis was prescribed interferon (IFN) β1a therapy. •The plasma triglycerides increased to >2000 mg/dL during IFN β1a therapy. •GPIHBP1 autoantibodies that blocked LPL binding appeared during IFN β1a therapy. •After stopping IFN β1a, the triglycerides normalized and the autoantibodies disappeared. •IFN β1a therapy likely caused the “GPIHBP1 autoantibody syndrome.” Background Autoantibodies against glycosylphosphatidylinositol-anchored high-density lipoprotein–binding protein 1 (GPIHBP1) cause chylomicronemia by blocking the ability of GPIHBP1 to bind lipoprotein lipase (LPL) and transport the enzyme to its site of action in the capillary lumen. Objective A patient with multiple sclerosis developed chylomicronemia during interferon (IFN) β1a therapy. The chylomicronemia resolved when the IFN β1a therapy was discontinued. Here, we sought to determine whether the drug-induced chylomicronemia was caused by GPIHBP1 autoantibodies. Methods We tested plasma samples collected during and after IFN β1a therapy for GPIHBP1 autoantibodies (by western blotting and with enzyme-linked immunosorbent assays). We also tested whether the patient's plasma blocked the binding of LPL to GPIHBP1 on GPIHBP1-expressing cells. Results During IFN β1a therapy, the plasma contained GPIHBP1 autoantibodies, and those autoantibodies blocked GPIHBP1's ability to bind LPL. Thus, the chylomicronemia was because of the GPIHBP1 autoantibody syndrome. Consistent with that diagnosis, the plasma levels of GPIHBP1 and LPL were very low. After IFN β1a therapy was stopped, the plasma triglyceride levels returned to normal, and GPIHBP1 autoantibodies were undetectable. Conclusion The appearance of GPIHBP1 autoantibodies during IFN β1a therapy caused chylomicronemia. The GPIHBP1 autoantibodies disappeared when the IFN β1a therapy was stopped, and the plasma triglyceride levels fell within the normal range. Autoantibodies against glycosylphosphatidylinositol-anchored high-density lipoprotein–binding protein 1 (GPIHBP1) cause chylomicronemia by blocking the ability of GPIHBP1 to bind lipoprotein lipase (LPL) and transport the enzyme to its site of action in the capillary lumen. A patient with multiple sclerosis developed chylomicronemia during interferon (IFN) β1a therapy. The chylomicronemia resolved when the IFN β1a therapy was discontinued. Here, we sought to determine whether the drug-induced chylomicronemia was caused by GPIHBP1 autoantibodies. We tested plasma samples collected during and after IFN β1a therapy for GPIHBP1 autoantibodies (by western blotting and with enzyme-linked immunosorbent assays). We also tested whether the patient's plasma blocked the binding of LPL to GPIHBP1 on GPIHBP1-expressing cells. During IFN β1a therapy, the plasma contained GPIHBP1 autoantibodies, and those autoantibodies blocked GPIHBP1's ability to bind LPL. Thus, the chylomicronemia was because of the GPIHBP1 autoantibody syndrome. Consistent with that diagnosis, the plasma levels of GPIHBP1 and LPL were very low. After IFN β1a therapy was stopped, the plasma triglyceride levels returned to normal, and GPIHBP1 autoantibodies were undetectable. The appearance of GPIHBP1 autoantibodies during IFN β1a therapy caused chylomicronemia. The GPIHBP1 autoantibodies disappeared when the IFN β1a therapy was stopped, and the plasma triglyceride levels fell within the normal range." @default.
• W2896745557 created "2018-10-26" @default.
• W2896745557 creator A5007276836 @default.
• W2896745557 creator A5010691279 @default.
• W2896745557 creator A5017019982 @default.
• W2896745557 creator A5019740099 @default.
• W2896745557 creator A5020332310 @default.
• W2896745557 creator A5027971993 @default.
• W2896745557 creator A5035358062 @default.
• W2896745557 creator A5046326191 @default.
• W2896745557 creator A5058675749 @default.
• W2896745557 creator A5060034527 @default.
• W2896745557 creator A5061756485 @default.
• W2896745557 creator A5071117617 @default.
• W2896745557 creator A5072735319 @default.
• W2896745557 creator A5075783365 @default.
• W2896745557 creator A5085166071 @default.
• W2896745557 creator A5085755071 @default.
• W2896745557 creator A5085828129 @default.
• W2896745557 creator A5090307190 @default.
• W2896745557 creator A5090781354 @default.
• W2896745557 date "2019-01-01" @default.
• W2896745557 modified "2023-10-14" @default.
• W2896745557 title "GPIHBP1 autoantibody syndrome during interferon β1a treatment" @default.
• W2896745557 cites W1538996896 @default.
• W2896745557 cites W1584226993 @default.
• W2896745557 cites W1936917066 @default.
• W2896745557 cites W1968856381 @default.
• W2896745557 cites W1984259997 @default.
• W2896745557 cites W2046730124 @default.
• W2896745557 cites W2047981682 @default.
• W2896745557 cites W2050865764 @default.
• W2896745557 cites W2052243816 @default.
• W2896745557 cites W2053183183 @default.
• W2896745557 cites W2057821480 @default.
• W2896745557 cites W2058959412 @default.
• W2896745557 cites W2059895389 @default.
• W2896745557 cites W2063780291 @default.
• W2896745557 cites W2066718881 @default.
• W2896745557 cites W2114689820 @default.
• W2896745557 cites W2120437898 @default.
• W2896745557 cites W2122475146 @default.
• W2896745557 cites W2122955674 @default.
• W2896745557 cites W2133779525 @default.
• W2896745557 cites W2165239524 @default.
• W2896745557 cites W2168084616 @default.
• W2896745557 cites W2223162642 @default.
• W2896745557 cites W2277423850 @default.
• W2896745557 cites W2317043038 @default.
• W2896745557 cites W2553162654 @default.
• W2896745557 cites W2559898767 @default.
• W2896745557 cites W2564594087 @default.
• W2896745557 cites W2585200153 @default.
• W2896745557 cites W2593860298 @default.
• W2896745557 cites W2605150564 @default.
• W2896745557 cites W2626639750 @default.
• W2896745557 cites W2635596260 @default.
• W2896745557 cites W2767062979 @default.
• W2896745557 cites W2789766907 @default.
• W2896745557 cites W2790854576 @default.
• W2896745557 cites W72762648 @default.
• W2896745557 doi "https://doi.org/10.1016/j.jacl.2018.10.004" @default.
• W2896745557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6379125" @default.
• W2896745557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30514621" @default.
• W2896745557 hasPublicationYear "2019" @default.
• W2896745557 type Work @default.
• W2896745557 sameAs 2896745557 @default.
• W2896745557 citedByCount "15" @default.
• W2896745557 countsByYear W28967455572019 @default.
• W2896745557 countsByYear W28967455572020 @default.
• W2896745557 countsByYear W28967455572022 @default.
• W2896745557 countsByYear W28967455572023 @default.
• W2896745557 crossrefType "journal-article" @default.
• W2896745557 hasAuthorship W2896745557A5007276836 @default.
• W2896745557 hasAuthorship W2896745557A5010691279 @default.
• W2896745557 hasAuthorship W2896745557A5017019982 @default.
• W2896745557 hasAuthorship W2896745557A5019740099 @default.
• W2896745557 hasAuthorship W2896745557A5020332310 @default.
• W2896745557 hasAuthorship W2896745557A5027971993 @default.
• W2896745557 hasAuthorship W2896745557A5035358062 @default.
• W2896745557 hasAuthorship W2896745557A5046326191 @default.
• W2896745557 hasAuthorship W2896745557A5058675749 @default.
• W2896745557 hasAuthorship W2896745557A5060034527 @default.
• W2896745557 hasAuthorship W2896745557A5061756485 @default.
• W2896745557 hasAuthorship W2896745557A5071117617 @default.
• W2896745557 hasAuthorship W2896745557A5072735319 @default.
• W2896745557 hasAuthorship W2896745557A5075783365 @default.
• W2896745557 hasAuthorship W2896745557A5085166071 @default.
• W2896745557 hasAuthorship W2896745557A5085755071 @default.
• W2896745557 hasAuthorship W2896745557A5085828129 @default.
• W2896745557 hasAuthorship W2896745557A5090307190 @default.
• W2896745557 hasAuthorship W2896745557A5090781354 @default.
• W2896745557 hasBestOaLocation W28967455572 @default.
• W2896745557 hasConcept C126322002 @default.
• W2896745557 hasConcept C134018914 @default.
• W2896745557 hasConcept C159654299 @default.
• W2896745557 hasConcept C163764329 @default.
• W2896745557 hasConcept C171089720 @default.

• next